Scroll Top
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles
Home
»
New data suggest enzyme modulator may slow Parkinson’s - Perspectives from Gain Therapeutics
Related Posts
Menu
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles
Related Posts
New data suggest enzyme modulator may slow Parkinson’s
Longevity.Technology
January 9, 2026
New data suggest enzyme modulator may slow Parkinson’s
Related Posts
Post navigation
Previous Post
Empowered Patient Podcast: Reality Check from Biotech Leaders on Using AI in Drug Discovery with BioXcel Therapeutics Gain Therapeutics iBio
Next Post
Early trial data suggest GT-02287 may aid Parkinson’s symptoms
Latest Articles
Clear Filters
June 10, 2026
Four emerging technologies reshaping neurology in 2026
https://www.labiotech.eu/in-depth/neurology-technology/
Read More
June 9, 2026
Bial drops pariceract after Phase IIb failure in GBA-associated Parkinson’s
https://european-biotechnology.com/latest-news/bial-drops-pariceract-after-phase-iib-failure-in-gba-associated-parkinsons/
Read More
May 27, 2026
Gain Therapeutics expands ‘compelling’ evidence base for Parkinson’s candidate
https://finance.yahoo.com/sectors/healthcare/articles/gain-therapeutics-expands-compelling-evidence-043446986.html
Read More
Close
About us
Overview
Leadership Team
Board of Directors
Clinical Advisory Board
Partners
Careers
Science and Technology
Platform Technology
Science
Posters
Publications
Pipeline
Investors & Media
Overview
News & Events
Stock Information
Analyst Coverage
Investor Resources
SEC Filings
Governance Documents
Contact Us
Perspectives
Events and Team Interviews
Parkinson 101
Technical Articles
